Kazia Therapeutics will report the full results at a future scientific meeting.
Kazia Therapeutics reported final data from a phase 1 study of cantrixil, a cyclodextrin-encapsulated, third-generation super-benzopyran (SBP) compound with potential antineoplastic activity.
In a statement, the company reported that the trial achieved it's primary objective, determining the maximum-tolerated dose of 5 mg/kg. The study involved 25 patients with advanced metastatic ovarian cancer at 6 sites in the United States and Australia; 11 took part in a dose-escalation arm and 14 took part in a dose-expansion arm.
Overall, 16 patients were evaluable for efficacy, with 1 patient demonstrating a complete response (CR) and 2 demonstrating a partial response, based on RECIST criteria, for an overall response rate of 19%. The patient with the CR remains in remission 3 years after the last dose of cantrixil.
The drug’s main adverse events were abdominal pain, vomiting, and nausea.
"This was a heavily pre-treated population, comprising patients with very advanced disease,” said the Australian lead investigator, Associate Professor Jim Coward, MBBS, PhD, of Icon Cancer Centre. “Existing treatment options for such patients are limited, and there remains an urgent need for new therapies. My colleagues and I are excited by the potential for cantrixil to provide benefit here, and we look forward to seeing the drug move forward in its development.”
Full data from the phase 1 study will be presented at a future scientific meeting, according to the statement from Kazia.
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More